Estradiol vaginal - Allergan

Drug Profile

Estradiol vaginal - Allergan

Alternative Names: WC 3011

Latest Information Update: 05 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Warner Chilcott
  • Developer Allergan
  • Class Antineoplastics; Estradiol congeners; Estrenes; Hormonal replacements; Small molecules
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Atrophic vaginitis

Most Recent Events

  • 01 Dec 2016 Warner Chilcott completes a phase II trial in Atrophic vaginitis (In adults, In the elderly) in USA (NCT02670785)
  • 01 Feb 2016 Phase-II clinical trials in Atrophic vaginitis (In adults, In the elderly) in USA (Vaginal, capsule) (NCT02670785)
  • 01 Jan 2016 Warner Chilcott plans a phase II trial for Atrophic vaginitis in USA (NCT02670785)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top